Drug intelligence / Profile preview

PM-CON:SMC2

Development stage: Preclinical
Modality: Nanoparticles → Drug Delivery Systems, Antibody-Based Therapeutics
Administration: In Vitro (cellular Uptake Shown By Incubation In Cell Culture; No In Vivo Or Clinical Administration Described)

Overview

PM-CON:SMC2 is a **nanomedicine formulation comprising polymeric micelles (PM)**—specifically Pluronic F127 polymeric micelles—**surface-conjugated with anti-SMC2 monoclonal antibodies** for intracellular delivery to tumor cells. This formulation is designed to target and inhibit the **structural maintenance of chromosomes protein 2 (SMC2)**, a key component of the condensin complex required for chromosome condensation and mitosis, and overexpressed in various cancers. **PM-CON:SMC2 enhances intracellular antibody uptake, induces cytotoxicity (not seen with free antibody), and causes G1 cell cycle arrest in colon (HCT116) and breast cancer (MDA-MB-231) cells**, especially in cancer stem cell (CSC) populations. The strategy aims to eradicate CSCs, potentially improving outcomes and reducing recurrence and metastasis. The platform is experimental and not yet approved for clinical use. There is no indication from available data that it has advanced to clinical trials.

Brand names: PM-CON:SMC2
Other names: PM-CON:SMC2

Targets

SMC2 (Ras-related protein Rab-33B)

Beyond the preview

Go deeper on PM-CON:SMC2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PM-CON:SMC2.

Explore the full profile